G&E’s False Claims Litigation Group represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 billion recovery for the federal and state governments.

G&E’s efforts on behalf of the lead whistleblower against Abbott Laboratories served as a catalyst for a $1.6 billion recovery for federal and state governments. The case concerned unlawful marketing of Abbott’s anti-epileptic drug Depakote.

G&E represented one of several whistleblowers that resulted in a $1.04 billion recovery for the federal and state governments. The suit arose from alleged misrepresentation by GlaxoSmithKline in its promotion of drug Advair.

G&E served as co-lead counsel in a derivative and class action suit successfully challenging $1.2 billion in back-dated options granted to then-CEO of health care provider UnitedHealth Group. The $922 million settlement is the largest settlement in the history of derivative litigation in any jurisdiction.

G&E was lead counsel in a securities class action against Pfizer concerning its multi-billion-dollar arthritis drugs, Celebrex and Bextra. Plaintiffs alleged that Pfizer misrepresented the cardiovascular safety of the drugs.

G&E represented two key whistleblowers behind a $257.4 million settlement between drugmaker Wyeth Pharmaceuticals and the U.S. Department of Justice stemming from alleged marketing abuses of Wyeth’s powerful immunosuppressant drug Rapamune.

G&E served as co-lead counsel in a securities class action settlement against Merck after the drugmaker’s stock price plummeted and shareholders lost billions of dollars. The case related to the company’s anti-cholesterol drug, Vytorin.

One of the largest derivative case settlements was reached in 2020, concerning failures of Board oversight at McKesson. The case related to the company’s role in the increase of opioid drug abuse in the United States.

G&E achieved a major settlement on behalf of purchasers of anti-HIV medicines in an antitrust class action.

As consumer subclass counsel and member of the steering committee, G&E attorneys obtained a $41.5 million recovery on behalf of consumers who overpaid for Merck Vytorin and Zetia, which defendants deceptively marketed as being more effective than other anti-cholesterol drugs.

G&E represented the Attorney General for the State of Mississippi in litigation against pharmaceutical manufacturer GlaxoSmithKline for claims arising out of the company’s misleading marketing and promotion of nine drugs, including blockbuster products Paxil, Wellbutrin, Advair, and Zofran.

In a major whistleblower settlement, G&E, working with the U.S. Department of Justice and the U.S. Attorney’s office in South Carolina, reached an agreement with Amgen resolving claims that it paid kickbacks to long-term care pharmacies so that elderly patients in nursing homes across the nation would be switched to or placed on the company’s drug, Aranesp.